DK52089A - Middel til behandling af nyresygdomme - Google Patents

Middel til behandling af nyresygdomme

Info

Publication number
DK52089A
DK52089A DK052089A DK52089A DK52089A DK 52089 A DK52089 A DK 52089A DK 052089 A DK052089 A DK 052089A DK 52089 A DK52089 A DK 52089A DK 52089 A DK52089 A DK 52089A
Authority
DK
Denmark
Prior art keywords
treatment
medicine
kidney diseases
igf
renal
Prior art date
Application number
DK052089A
Other languages
English (en)
Other versions
DK52089D0 (da
DK169232B1 (da
Inventor
Ernst Rudolf Froesch
Hans-Peter Guler
Christoph Schmid
Juergen Zapf
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of DK52089D0 publication Critical patent/DK52089D0/da
Publication of DK52089A publication Critical patent/DK52089A/da
Application granted granted Critical
Publication of DK169232B1 publication Critical patent/DK169232B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
DK052089A 1988-02-05 1989-02-03 Anvendelse af IGF I til fremstilling af et farmaceutisk præparat til behandling af nyresygdomme DK169232B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP88810071 1988-02-05
EP88810071 1988-02-05

Publications (3)

Publication Number Publication Date
DK52089D0 DK52089D0 (da) 1989-02-03
DK52089A true DK52089A (da) 1989-08-06
DK169232B1 DK169232B1 (da) 1994-09-19

Family

ID=8200570

Family Applications (1)

Application Number Title Priority Date Filing Date
DK052089A DK169232B1 (da) 1988-02-05 1989-02-03 Anvendelse af IGF I til fremstilling af et farmaceutisk præparat til behandling af nyresygdomme

Country Status (10)

Country Link
US (1) US5106832A (da)
EP (1) EP0327503B1 (da)
JP (1) JP2783825B2 (da)
KR (1) KR0131088B1 (da)
AT (1) ATE86496T1 (da)
AU (1) AU621583B2 (da)
CA (1) CA1336400C (da)
DE (1) DE68905203T2 (da)
DK (1) DK169232B1 (da)
ZA (1) ZA89813B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128320A (en) * 1990-01-18 1992-07-07 Genentech, Inc. Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
CA2109820A1 (en) * 1992-03-24 1993-09-30 George N. Cox Refolding and purification of insulin-like growth factor i
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
JPH09509141A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法
US6812208B2 (en) 1993-12-23 2004-11-02 Neuronz Ltd. Methods to improve neural outcome
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5837675A (en) * 1995-02-03 1998-11-17 Brox; Alan G. Synergistic effect of insulin-like growth factor-I and erythropoietin
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
JPH0995455A (ja) * 1995-09-29 1997-04-08 Sumitomo Pharmaceut Co Ltd 腎機能改善剤
US5985830A (en) * 1996-09-16 1999-11-16 Dalhousie University Use of IGF-I for the treatment of kidney disorders
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US20030069177A1 (en) 2000-05-16 2003-04-10 Genentech, Inc. Method for treating cartilage disorders
US7074762B2 (en) * 1998-01-05 2006-07-11 Washington University Composition and method for improving function of embryonic kidney transplants
IL143834A0 (en) * 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
EP1141014B1 (en) 1999-01-06 2004-12-08 Genentech, Inc. Insulin-like growth factor (igf) i mutant variant
ES2331150T3 (es) * 2001-02-09 2009-12-22 Genentech, Inc. Metodos para identificar agonistas indirectos de igf-1.
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
EP1401808B1 (en) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe analogs and peptidomimetics
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) * 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
NZ553057A (en) * 2004-08-30 2009-12-24 Tercica Inc Method and device for diagnosing and treating insulin-like growth factor deficiency disorders
US20210008172A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE220101T1 (de) * 1983-04-25 2002-07-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinähnlichen wachstumsfaktoren

Also Published As

Publication number Publication date
ZA89813B (en) 1989-09-27
JP2783825B2 (ja) 1998-08-06
CA1336400C (en) 1995-07-25
EP0327503A1 (en) 1989-08-09
JPH01226827A (ja) 1989-09-11
DK52089D0 (da) 1989-02-03
KR0131088B1 (ko) 1998-04-17
KR890012666A (ko) 1989-09-18
US5106832A (en) 1992-04-21
DE68905203D1 (de) 1993-04-15
DE68905203T2 (de) 1993-07-22
AU621583B2 (en) 1992-03-19
ATE86496T1 (de) 1993-03-15
AU2899889A (en) 1989-08-10
DK169232B1 (da) 1994-09-19
EP0327503B1 (en) 1993-03-10

Similar Documents

Publication Publication Date Title
DK52089A (da) Middel til behandling af nyresygdomme
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
DK85786A (da) Biologisk aktive fragmenter af human antihaemofilisk faktor og fremgangsmaade til fremstilling deraf
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DK333788A (da) Farmaceutisk praeparat til behandling af oedelagt bruskvaev
ATE81984T1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
DK184890A (da) Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme
DE3682229D1 (de) Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
EP0270690A4 (en) MEDICINES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER AND KIDNEY DISEASES.
ATE121100T1 (de) Ein neues thrombomodulin ähnliches glykoprotein erhältlich aus harn.
DK47089D0 (da) Middel med oedelaeggende virkning paa maligne tumorer, fremgangsmaade til fremstilling af saadanne midler og anvendelse af disse til terapeutisk behandling af cancer
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
DK598288A (da) Vaeskeformig farmaceutisk sammensaetning til behandling af hoste og oemhed i halsen
DE3872881D1 (de) Arzneimittelzusammensetzung zur vorbeugung und behandlung bakterieller und viraler krankheiten.
DK10188A (da) Middel til behandling af virussygdomme
FI952170A0 (fi) Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
JPS56125310A (en) Preparation of protein solution consisting essentially of lipoprotein of plasma with high specific gravity and serum albumin
DK103087D0 (da) Middel til behandling af kroniske tilstoppende lungesygdomme
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
DK417889A (da) Anvendelse af 2-azabicyklo(2.2.2.)-carboxylsyrederivater til fremstilling af medicinske produkter til behandling af vaskulaere sygdomme
DE3770133D1 (de) Arzneimittel zur behandlung und prophylaxe von leber- und nierenkrankheiten.
ATE63457T1 (de) Arzneimittel zur behandlung und prophylaxe von leber- und nierenkrankheiten.

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired